extract: 2025-12-01-who-glp1-global-guidelines-obesity

Pentagon-Agent: Ganymede <F99EBFA6-547B-4096-BEEA-1D59C3E4028A>

domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md

@@ -47,6 +47,12 @@ MASH/NASH is projected to become the leading cause of liver transplantation. GLP
 
 The BALANCE Model directly addresses the chronic use inflation problem by requiring lifestyle interventions alongside medication. If lifestyle supports can sustain metabolic benefits after medication discontinuation, the model could demonstrate a pathway to positive net cost impact. The 6-year test window (through 2031) will provide empirical data on whether combined intervention changes the chronic use economics.
 
+
+### Additional Evidence (extend)
+*Source: [[2025-12-01-who-glp1-global-guidelines-obesity]] | Added: 2026-03-16*
+
+WHO issued conditional recommendations (not full endorsement) for GLP-1s in obesity treatment, acknowledging 'limited long-term evidence.' The conditional framing and emphasis on cost-effectiveness analysis, budget impact, and ethical implications by country income level suggests uncertainty about whether the chronic use economics will prove sustainable, especially in low/middle-income countries where WHO guidelines have greatest influence.
+
 ---
 
 Relevant Notes:

domains/health/medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md

@@ -41,6 +41,12 @@ The Commonwealth Fund's 2024 Mirror Mirror international comparison provides the
 
 The NHS paradox—ranking 3rd overall while having catastrophic specialty access—provides supporting evidence that medical care's contribution to health outcomes is limited. A system can have multi-year waits for specialty procedures yet still rank highly in overall health system performance because primary care, equity, and universal coverage (which address behavioral and social factors) matter more than specialty delivery speed for population health outcomes.
 
+
+### Additional Evidence (confirm)
+*Source: [[2025-12-01-who-glp1-global-guidelines-obesity]] | Added: 2026-03-16*
+
+WHO's three-pillar framework for GLP-1 implementation explicitly positions medication as one component within a comprehensive approach requiring healthy diets, physical activity, professional support, and population-level policies. The framework treats obesity as a 'societal challenge requiring multisectoral action — not just individual medical treatment,' directly supporting the view that medical interventions alone cannot address health outcomes dominated by behavioral and social factors.
+
 ---
 
 Relevant Notes:

inbox/archive/2025-12-01-who-glp1-global-guidelines-obesity.md

@@ -7,9 +7,13 @@ date: 2025-12-01
 domain: health
 secondary_domains: []
 format: policy
-status: unprocessed
+status: enrichment
 priority: medium
 tags: [glp-1, WHO, global-health, obesity, guidelines, equity]
+processed_by: vida
+processed_date: 2026-03-16
+enrichments_applied: ["medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -39,3 +43,10 @@ WHO issued conditional recommendations for GLP-1 medicines in obesity treatment
 PRIMARY CONNECTION: [[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]
 WHY ARCHIVED: WHO's three-pillar framework challenges the pharmacological solution narrative and supports the view that GLP-1s are most effective when embedded in structural prevention infrastructure
 EXTRACTION HINT: The WHO position supports the BALANCE model's design but questions whether pharmaceutical solutions alone can address the obesity epidemic
+
+
+## Key Facts
+- WHO issued GLP-1 obesity treatment guidelines on December 1, 2025
+- WHO framework has three pillars: healthier environments through policy, protecting high-risk individuals, lifelong person-centered care
+- WHO recommendations are conditional, acknowledging limited long-term evidence
+- WHO emphasizes countries must consider local cost-effectiveness, budget impact, and ethical implications